Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors Journal Article


Authors: Valero, C.; Lee, M.; Hoen, D.; Weiss, K.; Kelly, D. W.; Adusumilli, P. S.; Paik, P. K.; Plitas, G.; Ladanyi, M.; Postow, M. A.; Ariyan, C. E.; Shoushtari, A. N.; Balachandran, V. P.; Hakimi, A. A.; Crago, A. M.; Long Roche, K. C.; Smith, J. J.; Ganly, I.; Wong, R. J.; Patel, S. G.; Shah, J. P.; Lee, N. Y.; Riaz, N.; Wang, J.; Zehir, A.; Berger, M. F.; Chan, T. A.; Seshan, V. E.; Morris, L. G. T.
Article Title: Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
Abstract: Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit for a wide range of cancer types. Because only a subset of patients experience clinical benefit, there is a strong need for biomarkers that are easily accessible across diverse practice settings. Here, in a retrospective cohort study of 1714 patients with 16 different cancer types treated with ICI, we show that higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall and progression-free survival, and lower rates of response and clinical benefit, after ICI therapy across multiple cancer types. Combining NLR with tumor mutational burden (TMB), the probability of benefit from ICI is significantly higher (OR = 3.22; 95% CI, 2.26-4.58; P < 0.001) in the NLR low/TMB high group compared to the NLR high/TMB low group. NLR is a suitable candidate for a cost-effective and widely accessible biomarker, and can be combined with TMB for additional predictive capacity. © 2021, The Author(s).
Journal Title: Nature Communications
Volume: 12
ISSN: 2041-1723
Publisher: Nature Publishing Group  
Date Published: 2021-02-01
Start Page: 729
Language: English
DOI: 10.1038/s41467-021-20935-9
PUBMED: 33526794
PROVIDER: scopus
PMCID: PMC7851155
DOI/URL:
Notes: Article -- Export Date: 1 March 2021 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Venkatraman Ennapadam Seshan
    385 Seshan
  2. Timothy Chan
    317 Chan
  3. Snehal G Patel
    417 Patel
  4. Michael Andrew Postow
    368 Postow
  5. Nadeem Riaz
    422 Riaz
  6. Nancy Y. Lee
    889 Lee
  7. Marc Ladanyi
    1334 Ladanyi
  8. George Plitas
    108 Plitas
  9. Richard J Wong
    421 Wong
  10. Paul K Paik
    257 Paik
  11. Luc Morris
    282 Morris
  12. Aimee Marie Crago
    106 Crago
  13. Charlotte Eielson Ariyan
    155 Ariyan
  14. Ahmet Zehir
    345 Zehir
  15. Ian Ganly
    433 Ganly
  16. Michael Forman Berger
    771 Berger
  17. Jatin P Shah
    725 Shah
  18. Abraham Ari Hakimi
    327 Hakimi
  19. Jesse Joshua Smith
    227 Smith
  20. Daniel William Kelly
    29 Kelly
  21. Douglas Robert Hoen
    10 Hoen
  22. Mark Lee
    16 Lee
  23. Jingming Wang
    8 Wang
  24. Kate Weiss
    10 Weiss